May 2006
Volume 47, Issue 13
ARVO Annual Meeting Abstract  |   May 2006
Intralesional Interferon Alfa–2b for Conjunctival Mucosa–Associated Lymphoid Tissue Lymphoma
Author Affiliations & Notes
  • M.A. Blasi
    Ophthalmology, University, L'Aquila, Italy
  • A.C. Tiberti
    Ophthalmology, Catholic University, Rome, Italy
  • A. Berarducci
    Ophthalmology, University, L'Aquila, Italy
  • E. Balestrazzi
    Ophthalmology, Catholic University, Rome, Italy
  • Footnotes
    Commercial Relationships  M.A. Blasi, None; A.C. Tiberti, None; A. Berarducci, None; E. Balestrazzi, None.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 2825. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M.A. Blasi, A.C. Tiberti, A. Berarducci, E. Balestrazzi; Intralesional Interferon Alfa–2b for Conjunctival Mucosa–Associated Lymphoid Tissue Lymphoma . Invest. Ophthalmol. Vis. Sci. 2006;47(13):2825.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate the long–term safety and effectiveness of intralesional interferon alfa–2b in the treatment of conjunctival mucosa–associated lymphoid tissue (MALT) lymphoma.

Methods: : Eleven patients (12 eyes) with conjunctival MALT lymphoma treated with a course of intralesional injections of interferon alfa–2b have been studied prospectively. Slit–lamp examination, incisional biopsy and systemic evaluation were performed before treatment in all patients. Immunohistopathological analysis of the specimens confirmed the diagnosis of extranodal B–cell lymphoma of the marginal zone (MALT, low–grade) in all cases and systemic disease was excluded in all patients. Interferon alfa–2b 1,500,000 IU injected intralesionally three times a week for four weeks followed by interferon alfa–2b 1,000,000 IU three times a week for further four weeks was administered to all patients. Slit lamp examination was performed 1,3, 6 months and then yearly after treatment, incisional biopsy was repeated 6 months after treatment.

Results: : Complete clinical remission was observed in 10 patients (10 eyes) at 3 months follow–up. Histopathological evaluation after treatment showed normal tissue with only inflammatory cells infiltrates in all cases. One patient with bilateral conjunctival involvement showed an incomplete clinical response. In 9 patients no local recurrence could be evidenced at a median follow–up of 64 months. One patient presented with a conjunctival recurrence 11 months after treatment and one patient presented with an orbital controlateral relapse 20 months after treatment. No local side effects were produced by the drug, but a transient flu–like syndrome was reported by the patients.

Conclusions: : Intralesional interferon alfa–2b is a minimally invasive but effective method of treatment for conjunctival MALT lymphoma as long term remission was achieved in 81.8% of patients.

Keywords: conjunctiva • oncology • injection 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.